Download Files:
Products Details
Product Description
– Lampalizumab (RG 7417) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research[1][2].
Web ID
– HY-P99298
Shipping
– Room temperature
Applications
– COVID-19-immunoregulation
Molecular Formula
– N/A
References
– [1]Yuan X, et al. Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Haematologica. 2017 Mar;102(3):466-475.|[2]Hanus J, et al. Current therapeutic developments in atrophic age-related macular degeneration. Br J Ophthalmol. 2016 Jan;100(1):122-7.
CAS Number
– 1278466-20-8
Molecular Weight
– 46.96 (kDa)
SMILES
– [Lampalizumab]
Clinical Information
– Phase 3
Research Area
– Inflammation/Immunology
Solubility
– H2O
Target
– Complement System
Pathway
– Immunology/Inflammation
Product type
– Inhibitory Antibodies
Disclaimer: All products are for Research use only unless clearly stated otherwise on the product datasheet. Datasheets provided on the website are drafts for reference purpose only and you are requested to always refer to the hard copy included in the kit for your experimentation. Agdia Products are available for delivery only in Canada.
